that is, in clinical trials to verify research hypotheses and experimental results. At one time, a sixth of the Institute's budget -more than $50 million of extramural funds -was devoted to clinical trials. During the past few years, we have also gotten more involved in knowledge transfer, e.g., demonstration and education activities. However, though the NHLBI and the National Institutes of Health (NIH) are still the mainstays at the knowledge acquisition end of the arrow, more and more agencies, public and private, are involved in helping deliver the fruits of health research into the health care community.
A Broadened Congressional Mandate
With the passage of the National Heart, Blood Vessel, Lung, and Blood Act of 1972, Congress made it clear that they intended the Institute to be involved in basic research and in research validation and technology assessment, and in education activities for the public and the professional.
Thus, we may discuss three activities in which the Institute is involved: First, acquisition of new knowledge, because the current state of knowledge is incomplete; second, research results that require further testing and validation before they can be properly applied; third, dissemination of research results that have been appropriately validated and thus can be widely applied toward better prevention, detection and treatment of disease.
In terms of distribution of the Institute's funds, approximately 80% of the Institute's dollars are spent in knowledge acquisition, about 15% in knowledge validation, and about 5% in knowledge dissemination.
The Role of the Council Though 80% of our funds go into knowledge acquisition, primarily through investigator-initiated research grants, the NHLBI Advisory Council spends much time discussing, assigning priorities to, and making funding decisions about activities in knowledge validation and knowledge dissemination. This is appropriate because activities in these areas are much easier to assess in terms of impact, likelihood of outcome, and needs. Medical Profession FIGURE 1. The National Heart, Lung, and Blood Institute continuum of research (Levy's arrow).
research are so unpredictable and so speculative that we rely primarily on the peer review system, on our many study sections -each composed of experts in a particular discipline -to make the funding recommendations about research grants. However, the actions that the Council takes also affect this basic area of knowledge acquisition. And the better it is at the translation end of the arrow, the more surely it helps guarantee the continued support of basic biomedical research. To achieve Institute goals in knowledge acquisition, validation and transfer, we have a number of support mechanisms. Research grant applications may be submitted by any investigator at any time. Here, the research goal and the plan for achieving it originate with the investigator himself. Other The Division of Extramural Affairs is not involved in the management of extramural programs, but serves as our interface with the other bodies of the NIH. It has another extremely important function: to review all applications that come in for research on heart, lung and blood diseases. Some of these applications may have been solicited by program divisions, but they become part of the heart, lung and blood portfolio only after independent review by the Division of Extramural Affairs.
The Division of Intramural Research is our separate research establishment. It is not involved in extramural funding decisions or in the management of extramural programs.
Programs of DHVD It would be impossible to discuss all of the NHLBI programs in terms of the arrow and the continuum of research, so I will focus on one division, the DHVD. Ten program areas are in this division. Four deal with major etiologic processes: arteriosclerosis, hypertension, congenital and rheumatic heart disease, and cardiomyopathy and infections of the heart. Three deal with the clinical sequelae of these processes: coronary heart disease, peripheral vascular disease and cerebrovascular disease. Two deal with the most serious clinical manifestations of these problems: arrhythmias, heart failure and shock. Finally, there is Arteriosclerosis, hypertension and coronary artery disease receive the majority of the research dollars and attention in the portfolio of the DHVD ( fig. 4 ). This is appropriate because of the magnitude of the health problems posed by these diseases. 
Hypertension: Research Expansion
Over the next 20 years, we learned about the tremendous complexity of hypertension. We learned about the involvement of the central and autonomic nervous systems in the control of blood pressure; the role of then-obscure hormones, such as kallikreins and kinins, prostaglandins, renin and angiotensin; the role of the vessel wall and its intrinsic reactivity; the role of the heart and kidneys; and the importance of nutrition and of salt and water balance. We got suggestions of the importance of psychologic and sociologic factors. But despite all we have learned about the complexities of hypertension, in more than 95% of the patients suffering from the disease, we still don't know its cause. From epidemiologic studies like those at Framingham, Tecumseh, and elsewhere, we have learned that hypertension is the most important factor contributing to some 500,000 strokes each year, about 170,000 of them fatal, making stroke the third leading cause of death in the United States.
We have also learned that hypertension is a major accelerating factor in the process of atherosclerosis, a disease responsible for 1.25 million heart attacks and some 650,000 heart attack deaths each year. We estimate conservatively that hypertension costs this country more than $8 billion annually in health care costs, lost wages and productivity, not to mention the costs of suffering attending the premature loss or disability of a loved one. blood pressure levels above 105 mm Hg diastolicwas cost-effective, by virtue of reducing mortality from stroke, heart failure and renal failure. Because of the promising results of this trial and because of the knowledge of the magnitude of the hypertension problem, the availability of effective drugs at that time, and of the realization that these drugs could prevent much disability and death, two programs -both enthusiastically supported and recommended by the NHLBI Advisory Councilwere begun in 1972. One was the NHBPEP, which was designed to disseminate knowledge to the public about what can and should be done about hypertension, based on existing knowledge about high blood pressure and its treatment. The other was the HDFP, a clinical trial with 14 participating centers designed to acquire new knowledge.
The National High Blood Pressure Education Program
In 1972, all too many were not alert to what could and should be done for hypertension. The majority of Americans who had hypertension were unaware of it. Most persons did not relate hypertension to its sequelae, such as stroke and heart failure. Many people confused hypertension with nervous tension.
Nor did all physicians know as much as they needed to know about hypertension and its treatment in 1972. Many physicians still accepted the tenet that perhaps elevated blood pressure should not be treated, lest critical organ perfusion pressures be compromised. Too few physicians were aware that they had to work closely with their patients to achieve and maintain good blood pressure control. They not only had to tell the patient that he had high blood pressure, but they had to describe in some detail what the problem was and what could and should be done about it. Too few physicians really took the time to think about or deal with problems of long-term adherence to prescribed therapy, e.g., persuading patients to take medicine when they felt well and getting them to continue taking medicine despite side effects that might make them not feel well. Too few physicians took on the task or were effective in the task of making patients understand that although medications could control the disease, they could not cure it, so lifetime treatment would probably be necessary.
NHBPEP: the Approach Thus, the NHBPEP, from its inception, was based on some simple premises. To the health care professional, we emphasized the high prevalence of hypertension, the fact that it was asymptomatic, that it was easy to detect, that effective therapy was available, but that adherence was essential.
To the general public, we emphasized the very high prevalence of hypertension; that many who have it may not know it, because one can't feel it; that it is easy to detect, requring only a simple, painless blood pressure check; that it can be controlled; and that, with long-term treatment, the risk of heart disease, stroke and renal failure can be reduced. NHBPEP: Some Promising Results Within the first 2-3 years of the program, we had evidence that, whereas initially about 50% of those with hypertension had been unaware of their disease, this had dropped to only 30% in the communities surveyed. Initially, it was estimated that, among Americans aware of their hypertension, only about 16% had their blood pressure under adequate control. After the program was initiated, a survey in the communities where the 14 HDFP participating centers were located indicated that 30% were receiving adequate treatment.
Spot surveys done in Westchester in 1975, Milwaukee in 1976 and Chicago in 1977 also confirmed that the number of hypertensives who were unaware of their disease was rapidly decreasing and that an increasing number of hypertensives -50% or more -were being treated, and indicated that 50% or more of these were under good control. Other survey data indicated that patient visits to their doctors for hypertension increased by almost 50% in the first 3-4 years of the program, while visits for all other causes had increased hardly at all.
It may be fortuitous, but we have also noted a temporal association between the NHBPEP and a precipitous fall in stroke deaths (table 2). Stroke deaths had been declining at a rate of about 1-1.5% per year in the 1960s. Since the inception of the program in 1972, stroke deaths have declined at the remarkable rate of over 5% a year, so that during the 1970s, the mortality rate has fallen by 40%. fig. 5 ). The output of publications peaked in 1975, but since then, has still remained much higher than it was earlier. This provides a dramatic example of how activities at one end of the continuum can affect the others.
NHBPEP helped stimulate biomedical interest in hypertension. This led, in turn, to a demand in 1976 that the Institute look into new opportunities in hypertension research, particularly with respect to causation, because until we know the causes of hypertension, we are unlikely to find a means of prevention. 1970 1971 1972 1973 1974 1975 1976 1977 A Council subcommittee appointed to consider such a trial concluded that it would require some 5000-10,000 subjects; would have to go on for 6 years; and, if done as a controlled, double-blind trial, would cost the Institute almost $100 million.
The estimated cost was a major concern, but there were others. The proposed double-blind trial would require a placebo-treated control group, and the consensus in the medical community was that persons with hypertension should not be denied treatment.
Moreover, it was anticipated that the dropout rate among patients in the control group might be unacceptably high.
But The HDFP has given us some exciting answers, but it has also raised new questions and given increased urgency to some old questions that had been previously identified. It has pointed up additional opportunities throughout the biomedical research continuum (table 1).
The Quest for Causes Clearly, lifelong treatment of hypertension can control its dreadful sequelae in as many as 60 million Americans; but developing effective means of prevention would offer an even more cost-effective approach. The results of the HDFP give increased importance to seeking answers about the basic cause or causes of hypertension.
Over the next several years, we will explore more aggressively the possible roles of disturbances of central and autonomic nervous system, endogenous hormone imbalances, adverse genetic influences, and sociologic and psychologic factors in the genesis of hypertension. We must also get a better understanding of factors that affect blood vessel tone, salt and water balance, and heart and kidney function. Some moves in this direction are already under way, such as the recent efforts to encourage research into the effect of hypertension on the microcirculation and on the effect of salt on hypertensive persons.
As There are still other questions in the health care area. What kind of demand would doing all that we know right now about hypertension put on our whole health care delivery system? Can our physicians handle all this alone, or to what extent might nursepractitioners, pharmacists, or paramedical personnel be mobilized toward the goal of getting hypertensive patients under therapy and encouraging compliance?
If we are going to deliver hypertension care now to 60 million Americans, costs will increase. However, benefits will increase and morbidity and mortality from hypertension-related disorders will decrease. Treatment: Returns on Investment About 5 years ago, when we knew only that it was beneficial to treat moderate and severe hypertension, we derived a cost-benefit analysis. We concluded that, among those below age 65 years in the working class, for every dollar spent we would save $1.25 because of decreased morbidity and mortality. If we were to add the 40 million or so mild hypertensives into this treatment program, would the cost-benefit ratio still be $1.25 or would it diminish? Might we end up spending more than we save? Should we provide free therapy to indigent hypertensives who cannot afford high blood pressure drugs? Should reimbursements be provided by insurance companies to hypertensives who go on treatment and stay on treatment?
Still other questions must be answered. But let me desist long enough to say that the HDFP has been very successful. It has answered the questions that we asked; we shouldn't be too unhappy that we have been provided with a new set of questions.
The Institute plans to hold a workshop this year to focus on the implications of HDFP for health research and health care, to assign priorities to some of these issues, and to investigate the feasibility of participation by other federal agencies in areas outside the usual domain of this Institute.
The HDFP went on during a period when we were already seeing a dramatic increase in attention to hypertension and a dramatic fall in stroke mortality. Nevertheless, the results of this study indicate Recent medical studies6812 usually allocate patients to medical therapy in an uncontrolled manner and probably contain many patients considered less likely to benefit from CABG. Therefore, the medically treated group probably contains inoperable patients and also high-risk patients; these higher-risk patients may be unidentifiable at present. When used in matched control studies,'3-'6 these patients may not be an appropriate group to compare with current surgically treated patients, at least as far as survival is concerned.
"Normal" or U.S. Population
Comparison of CABG patients to the U.S. population'6 may be of limited value. The U.S. population contains not only normal people but also people with malignancy, renal and pulmonary failure, inoperable CAD, emotional disorders, and other diseases that put
